Statement of changes in beneficial ownership of securities Submitted by amarin on Tue, 04/02/2019 - 00:26 Home Read more about Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities Submitted by amarin on Tue, 04/02/2019 - 00:24 Home Read more about Statement of changes in beneficial ownership of securities
Report of unscheduled material events or corporate event Submitted by amarin on Mon, 04/01/2019 - 21:12 Home Read more about Report of unscheduled material events or corporate event
Vascepa® Granted Priority Review Status from Health Canada New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with Amarin Submitted by amarin on Fri, 03/29/2019 - 23:32 Home Read more about Vascepa® Granted Priority Review Status from Health Canada New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with Amarin
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study Submitted by amarin on Thu, 03/28/2019 - 20:53 Home Read more about Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study Submitted by amarin on Thu, 03/28/2019 - 09:01 Home Read more about New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study
Initial filing by director officer or owner of more than ten percent. Submitted by amarin on Thu, 03/21/2019 - 00:21 Home Read more about Initial filing by director officer or owner of more than ten percent.
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session Submitted by amarin on Tue, 03/19/2019 - 10:04 Home Read more about Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels Submitted by amarin on Mon, 03/18/2019 - 20:20 Home Read more about Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™ Submitted by amarin on Mon, 03/18/2019 - 13:04 Home Read more about Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
